Linfeng Luo

651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

LILRB2+ monocytes reshape the immune activation landscape in immunotherapy with non-small cell lung cancer: Evidence from real-world cohorts and single-cell analyses.

LILRB2+ monocytes reshape the immune activation landscape in immunotherapy with non-small cell lung cancer: Evidence from real-world cohorts and single-cell analyses.

Journal: International journal of biological macromolecules

Published: January 09, 2026

Epidural haematoma following vertebroplasty for osteoporosis compression fracture: A case report.

Epidural haematoma following vertebroplasty for osteoporosis compression fracture: A case report.

Journal: International journal of surgery case reports

Published: May 16, 2025

Causality between genetically predicted type 2 diabetes and ankle fracture risk: A 2-sample Mendelian randomization study.

Causality between genetically predicted type 2 diabetes and ankle fracture risk: A 2-sample Mendelian randomization study.

Journal: Medicine

Published: October 07, 2024

Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.

Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.

Journal: JAMA network open

Published: March 07, 2024

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC.

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 25, 2023

Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy.

Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy.

Journal: NPJ precision oncology

Published: February 28, 2023

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer.

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer.

Journal: Frontiers in immunology

Published: February 19, 2023

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor.

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor.

Journal: Therapeutic advances in medical oncology

Published: February 08, 2023

Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy.

Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy.

Journal: iScience

Published: January 12, 2023

[Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.

[Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.

Journal: Immunologic research

Published: September 13, 2022

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.

Journal: Frontiers in immunology

Published: June 02, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026